Evidence map›Paper›PMID 37638015›Full record

ArticleFrontiers in immunology2023

Myeloid-associated differentiation marker is associated with type 2 asthma and is upregulated by human rhinovirus infection.

Sasipa Tanyaratsrisakul, Alane Blythe C Dy, Francesca Polverino, Mari Numata, Julie G Ledford

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sasipa TanyaratsrisakulAsthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, United States.
Alane Blythe C DyAsthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, United States.
Francesca PolverinoDepartment of Medicine, Baylor College of Medicine, Houston, TX, United States.
Mari NumataDepartment of Medicine, National Jewish Health, Denver, CO, United States.
Julie G LedfordAsthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, United States.
University of Arizona · USBaylor College of Medicine · USUniversity of Colorado Denver · US

Funding

SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Tollip inhibits IL-33 signaling during airway influenza virus infectionU19AI125357 · NIAID · UNIVERSITY OF ARIZONA · PI VOELKER, DENNIS R. · 2016 to 2025
$14.7M
Transcriptomic and Genetic Endotyping of Exacerbation-Prone AsthmaticsP01HL132821 · NHLBI · NATIONAL JEWISH HEALTH · PI SEIBOLD, MAX A · 2017 to 2021
$9.0M
Defining mechanisms of CC16 on epithelial-driven host responses to pathogensR01HL142769 · NHLBI · UNIVERSITY OF ARIZONA · PI Julie Gunnells Ledford · 2019 to 2026
$4.2M
NHLBI NIH HHS P01 HL132821NHLBI NIH HHS R01 HL142769NIAID NIH HHS U19 AI125357NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Background: Human rhinoviruses are known to predispose infants to asthma development during childhood and are often associated with exacerbations in asthma patients. MYADM epithelial expression has been shown to associate with asthma severity. The goal of this study was to determine if MYADM expression patterns were altered in asthma and/or rhinovirus infection and if increased MYADM expression is associated with increased asthma-associated factors. Methods: Utilizing H1HeLa cells and differentiated primary human airway epithelial cells (AECs), we measured the expression of MYADM and inflammatory genes by qRT-PCR in the presence or absence of RV-1B infection or poly I:C treatment and with siRNA knockdown of MYADM. Expression of MYADM in the asthmatic lung was determined in the ovalbumin (ova)-challenged murine model. Results: MYADM expression was upregulated in the lungs from ova-treated mice and in particular on the subsurface vesicle membrane in airway epithelial cells. Upon infection with RV-1B, human AECs grown at an air-liquid interface had increased the MYADM expression predominantly detected in ciliated cells. We found that the presence of MYADM was required for expression of several inflammatory genes both in a resting state and after RV-1B or poly I:C treatments. Conclusions: Our studies show that in a mouse model of asthma and during RV-1B infection of primary human AECs, increased MYADM expression is observed. In the mouse model of asthma, MYADM expression was predominantly on the luminal side of airway epithelial cells. Additionally, MYADM expression was strongly associated with increases in inflammatory genes, which may contribute to more severe asthma and RV-linked asthma exacerbations.

Indexed as

AsthmaEnterovirus InfectionsAnimalsAntigens, DifferentiationDisease Models, AnimalHumansInfantMiceOvalbuminPoly I-CRhinovirusAntigens, DifferentiationOvalbuminPoly I-Cairway epithelial cellsasthmahuman rhinoviruslung inflammationMYADM

Identifiers

PMID37638015
PMCPMC10450947
OpenAlexW4385758852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.